Botox approved for overactive bladder
Source: Agencies |
January 20, 2013, Sunday
|
Print Edition
Print Edition
THE popular Botox wrinkle treatment made by Allergan Inc has been approved to treat adults with overactive bladder who cannot tolerate or failed to be helped by other drugs for the condition, the US Food and Drug Administration said on Friday.
Botox injected into the bladder muscle causes the bladder to relax, increasing its storage capacity and reducing episodes of urinary incontinence, or leakage.
"Clinical studies have demonstrated Botox's ability to significantly reduce the frequency of urinary incontinence," Hylton Joffe, director of the FDA's Division of Reproductive and Urologic Products, said in a statement. "Today's approval provides an important additional treatment option for patients with overactive bladder, a condition that affects an estimated 33 million men and women in the United States."
Botox had previously been approved for other non-cosmetic uses, such as migraine headaches, severe underarm sweating and loss of bladder control due to nerve damage.
Allergan, which has yet to report full year financial results, said it expects 2012 Botox sales of US$1.76 billion to US$1.8 billion. Analysts have said that approval for overactive bladder could add more than US$200 million a year to Botox sales. The treatment can be repeated when the effect wears off, but with a gap of at least 12 weeks between treatments.
About 3.2 million Americans suffering from overactive bladder take oral medications from a class of drugs called anticholinergics.
Botox injected into the bladder muscle causes the bladder to relax, increasing its storage capacity and reducing episodes of urinary incontinence, or leakage.
"Clinical studies have demonstrated Botox's ability to significantly reduce the frequency of urinary incontinence," Hylton Joffe, director of the FDA's Division of Reproductive and Urologic Products, said in a statement. "Today's approval provides an important additional treatment option for patients with overactive bladder, a condition that affects an estimated 33 million men and women in the United States."
Botox had previously been approved for other non-cosmetic uses, such as migraine headaches, severe underarm sweating and loss of bladder control due to nerve damage.
Allergan, which has yet to report full year financial results, said it expects 2012 Botox sales of US$1.76 billion to US$1.8 billion. Analysts have said that approval for overactive bladder could add more than US$200 million a year to Botox sales. The treatment can be repeated when the effect wears off, but with a gap of at least 12 weeks between treatments.
About 3.2 million Americans suffering from overactive bladder take oral medications from a class of drugs called anticholinergics.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
